ReviewFrontiers in oncology2025
IQGAP1: cross-disease target via receptor-pathway networks.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- miR-124 Ameliorates Spatial Memory Deficits in Rats Exposed to Single-Prolonged Stress by Downregulating IQGAP1 to Regulate Actin-Binding Proteins and Apoptosis in Hippocampal Neurons.Molecular neurobiology · 2026Article
- IQGAP Family Proteins in Colorectal Cancer: Molecular Mechanisms and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2026Review
- Integrative phosphoproteomic analysis reveals co-regulatory phosphorylation networks of rhotekin in cancer progression.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IQGAP1, a versatile scaffolding protein, critically regulates cytoskeletal organization, cell motility, proliferation, and signaling cascades. Beyond coordinating these cellular functions, it is increasingly recognized as a key driver in malignancies, immune dysfunction, metabolic dysregulation, and cardiovascular pathologies. By binding receptor tyrosine kinases, small GTPases, and downstream effectors, IQGAP1 modulates oncogenesis, immune evasion, and metabolic imbalance, while contributing to chemoresistance. This review synthesizes advances in IQGAP1's structural domains, disease-specific signaling networks, and therapeutic targeting strategies, emphasizing its translational potential in developing precision therapies for cancer, metabolic syndromes, and immune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.